蘭衞醫學(301060.SZ):2024年度預虧1.07億元-1.57億元
格隆匯1月16日丨蘭衞醫學(301060.SZ)公佈2024年度業績預吿,2024年歸屬於上市公司股東的淨利潤虧損1.07億元-1.57億元,上年同期虧損1.42億元;扣除非經常性損益後的淨利潤虧損1.0億元-1.48億元,上年同期虧損15,187.04萬元。
報吿期內,公司部分檢測業務的長賬齡應收賬款實現回款,導致本年度計提的信用減值損失較同期大幅下降。
結合公司實際經營情況及行業市場變化等影響,根據《企業會計準則第8號——資產減值》及相關會計政策規定計提資產減值損失,減值金額較同期大幅上升。最終減值金額由公司聘請的評估機構及審計機構進行評估和審計後確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.